Salvador Fudio

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Heart Rate Variability

Radiation Therapy

Top Venues

Pharmaceuticals (Basel, Switzerland)

Cancer chemotherapy and pharmacology

Life science alliance

This page only lists publications with an associated author ORCID identifier.

Publications

Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Irene Moreno-Candilejo, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Irene Moreno-Candilejo, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Jose F Varona, Pedro Landete, Jose Antonio Lopez-Martin, Vicente Estrada, Roger Paredes, Pablo Guisado-Vasco, Lucia Fernandez de Orueta, Miguel Torralba, Jesús Fortun, Roberto Vates, Jose Barberan, Bonaventura Clotet, Julio Ancochea, Daniel Carnevali, Noemi Cabello, Lourdes Porras, Paloma Gijon, Alfonso Monereo, Daniel Abad, Sonia Zuñiga, Isabel Sola, Jordi Rodon, Julia Vergara-Alert, Nuria Izquierdo-Useros, Salvador Fudio, Maria Jose Pontes, Beatriz de Rivas, Patricia Giron de Velasco, Antonio Nieto, Javier Gomez, Pablo Aviles, Rubin Lubomirov, Alvaro Belgrano, Belen Sopesen, Kris M White, Romel Rosales, Soner Yildiz, Ann-Kathrin Reuschl, Lucy G Thorne, Clare Jolly, Greg J Towers, Lorena Zuliani-Alvarez, Mehdi Bouhaddou, Kirsten Obernier, Briana Lynn McGovern, M Luis Rodriguez, Luis Enjuanes, Jose M Fernandez-Sousa, Nevan J Krogan, Jose M Jimeno, Adolfo García-Sastre
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. Life science alliance 5 (4) (2022)
Carlos Fernández-Teruel, Salvador Fudio, Rubin Lubomirov
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer. Cancer chemotherapy and pharmacology (2021)
Salvador Fudio, Josep Tabernero, Vivek Subbiah, Sant P Chawla, Victor Moreno, Federico Longo, Rafael Lopez, Antonio Anton, Jose Manuel Trigo, Geoffrey Shapiro, Woondong Jeong, Victor Manuel Villalobos, Rubin Lubomirov, Carlos Fernández-Teruel, Vicente Alfaro, Valentina Boni
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. Cancer chemotherapy and pharmacology 87 (1) (2020)
Carlos Fernández-Teruel, Ignacio González-García, Iñaki F Trocóniz, Rubin Lubomirov, Arturo Soto, Salvador Fudio
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer. Clinical pharmacokinetics 58 (3) (2020)